Central Administration of Recombinant IGF1 Is Neuroprotective in a Rodent Model of Acute Liver Failure
International Journal of Molecular Sciences · 16.04.2026 · 27 (8) · 3547
DOI: 10.3390/ijms27083547 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.04.2026. Verfasst von Yubo Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Liver Failure, Acute, Neuroprotective Agents, Hepatic Encephalopathy. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Acute liver failure is often accompanied by neurological disturbances collectively referred to as hepatic encephalopathy (HE), characterized by neuroinflammation and subsequent cognitive decline. Insulin-like growth factor 1 (IGF1) is a neuroprotective peptide with anti-inflammatory properties in the brain. The role of IGF1 in cognitive deficits and neuroinflammation during HE remains largely unexplored. In C57Bl/6 mice, HE was established through an intraperitoneal injection of azoxymethane (AOM), and tissues were collected at defined time points during disease development. IGF1 expression in the cortex was downregulated following AOM administration. Central infusion of recombinant mouse IGF1 (rmIGF1) before AOM injection resulted in delayed neurological impairment, reduced microglial activation, and decreased proinflammatory cytokine and chemokine production in AOM mice. In vitro, rmIGF1 and conditioned media derived from rmIGF1-treated primary neurons attenuated phagocytic activity and C–C motif chemokine ligand 2 (CCL2) production in the microglial cell line EOC-20. Collectively, our results show that IGF1, whose levels decline during HE, alleviates neuroinflammation and improves the pathological state of AOM-treated mice through the suppression of microglial activation and the regulation of neuron–microglia paracrine communication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA.
- Department of Innovation, Education and Technology, Baylor College of Medicine, Temple, TX 76508, USA.
- Department of Neurosurgery, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
- Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
ORCID-Profile: Yubo Wang, Matthew McMillin, Gabriel Frampton, Patrick Mireles, Sharon DeMorrow
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Wang, Y., McMillin, M., Frampton, G., Rhodes, K., Williams, E., Venter, J., Tyson, J., Gupta, E., Patankar, M., Mireles, P., & DeMorrow, S. (2026). Central Administration of Recombinant IGF1 Is Neuroprotective in a Rodent Model of Acute Liver Failure. International Journal of Molecular Sciences, 27(8), 3547. https://doi.org/10.3390/ijms27083547
Vancouver
Wang Y, McMillin M, Frampton G, Rhodes K, Williams E, Venter J, et al. Central Administration of Recombinant IGF1 Is Neuroprotective in a Rodent Model of Acute Liver Failure. International Journal of Molecular Sciences. 2026;27(8):3547. doi:10.3390/ijms27083547
BibTeX
@article{Wang2026,
author = {Wang, Yubo and McMillin, Matthew and Frampton, Gabriel and Rhodes, Kathryn and Williams, Elaina and Venter, Juliet and Tyson, Jace and Gupta, Esha and Patankar, Mihika and Mireles, Patrick and DeMorrow, Sharon},
title = {Central Administration of Recombinant IGF1 Is Neuroprotective in a Rodent Model of Acute Liver Failure},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3547},
doi = {10.3390/ijms27083547}
}
EUVIMED